DNAH12: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: DNAH12

NCBI ID: G201625

DNAH12

DNAH12: A Potential Drug Target for Cancer and Neurodegenerative Diseases

DNAH12, also known as DNAH12 variant 4, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. DNAH12 plays a crucial role in controlling the length of the telomeres, which are the protective caps at the end of chromosomes that prevent chromosomes from deteriorating or fusing with one another.

Recent studies have identified DNAH12 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. This is because DNAH12 is involved in many important cellular processes that are disrupted in these conditions, and drugs that can inhibit DNAH12 activity may have therapeutic benefits.

One of the key reasons for the potential of DNAH12 as a drug target is its involvement in the regulation of the cell cycle. DNAH12 is a key regulator of the G1 phase of the cell cycle, which is when cells prepare for cell division. During this phase, DNAH12 ensures that the cell has enough copies of its genetic material to divide properly. If DNAH12 is impaired or dysfunctional, it can cause the cell cycle to go out of control, leading to the formation of cancer cells.

Another potential drug target for DNAH12 is its role in the regulation of cell death. DNAH12 is involved in the programmed cell death (apoptosis) pathway, which is the process by which cells undergo natural programmed cell death. This is important for the development and maintenance of tissues and organs, and for the removal of damaged or dysfunctional cells.

In addition to its role in cell cycle regulation, DNAH12 is also involved in the regulation of DNA replication and gene expression. It is a key regulator of the DNA replication machinery, which is responsible for copying the genetic material from one chromosome to the other during the cell cycle. DNAH12 also interacts with the transcription factor p53, which is a key regulator of gene expression and DNA replication.

The identification of DNAH12 as a potential drug target or biomarker has important implications for the development of new treatments for a variety of diseases. By inhibiting DNAH12 activity, drugs can target the regulation of the cell cycle and cell death, and potentially lead to the inhibition of the growth and division of cancer cells. This has potential applications in the treatment of cancer, neurodegenerative diseases, and developmental disorders.

In conclusion, DNAH12 is a protein that is involved in various cellular processes that are critical for the development and maintenance of tissues and organs. Its regulation of the cell cycle, cell death, and DNA replication machinery makes it a potentially promising drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of DNAH12 in these processes and to identify effective treatments.

Protein Name: Dynein Axonemal Heavy Chain 12

Functions: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Involved in sperm motility; implicated in sperm flagellar assembly (By similarity)

The "DNAH12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets